Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
547.03
-0.86 (-0.16%)
At close: Nov 11, 2026, 4:00 PM EST
542.94
-4.09 (-0.75%)
After-hours: Nov 11, 2026, 7:51 PM EST
Vertex Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 12,952 | 11,971 | 11,020 | 9,869 | 8,931 | 7,573 |
Other Revenue | - | 30.7 | - | - | - | 1 |
| 12,952 | 12,001 | 11,020 | 9,869 | 8,931 | 7,574 | |
Revenue Growth | 10.48% | 8.90% | 11.66% | 10.51% | 17.91% | 22.06% |
Cost of Revenue | 5,853 | 5,561 | 5,161 | 4,425 | 3,608 | 2,842 |
Gross Profit | 7,099 | 6,441 | 5,859 | 5,444 | 5,323 | 4,732 |
Selling, General & Admin | 2,204 | 1,753 | 1,464 | 1,137 | 944.7 | 840.1 |
Operating Expenses | 2,204 | 1,753 | 1,464 | 1,137 | 944.7 | 840.1 |
Operating Income | 4,895 | 4,687 | 4,395 | 4,308 | 4,378 | 3,892 |
Interest Expense | -45.6 | -13.3 | -30.6 | -44.1 | -54.8 | -61.5 |
Interest & Investment Income | 482 | 490.9 | 598.1 | 614.7 | 144.6 | 4.9 |
Currency Exchange Gain (Loss) | 6.5 | -13.7 | -27.3 | -24.6 | -15.1 | -13.9 |
Other Non Operating Income (Expenses) | 7.6 | 17.3 | -49.3 | 9.3 | -0.6 | 1.7 |
EBT Excluding Unusual Items | 5,345 | 5,169 | 4,886 | 4,863 | 4,453 | 3,824 |
Merger & Restructuring Charges | -473.9 | - | - | - | - | - |
Gain (Loss) on Sale of Investments | 4.8 | -11.3 | -9.5 | -7.5 | -149.1 | 17.1 |
Asset Writedown | - | -379 | - | - | -13 | - |
Other Unusual Items | 2 | -2.1 | 0.5 | 51.6 | 57.5 | 3.1 |
Pretax Income | 4,759 | 4,643 | 248.5 | 4,380 | 4,232 | 2,730 |
Income Tax Expense | 783.2 | 690 | 784.1 | 760.2 | 910.4 | 388.3 |
Earnings From Continuing Operations | 3,976 | 3,953 | -535.6 | 3,620 | 3,322 | 2,342 |
Net Income | 3,976 | 3,953 | -535.6 | 3,620 | 3,322 | 2,342 |
Net Income to Common | 3,976 | 3,953 | -535.6 | 3,620 | 3,322 | 2,342 |
Net Income Growth | 8.19% | - | - | 8.96% | 41.84% | -13.63% |
Shares Outstanding (Basic) | 254 | 256 | 258 | 258 | 256 | 258 |
Shares Outstanding (Diluted) | 256 | 258 | 258 | 261 | 259 | 260 |
Shares Change | -1.01% | 0.04% | -1.00% | 0.54% | -0.31% | -1.33% |
EPS (Basic) | 15.67 | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 |
EPS (Diluted) | 15.55 | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 |
EPS Growth | 9.33% | - | - | 8.35% | 42.29% | -12.44% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 3,202 | 3,194 | -790.3 | 3,337 | 3,925 | 2,409 |
Free Cash Flow Per Share | 12.53 | 12.38 | -3.06 | 12.81 | 15.15 | 9.27 |
Gross Margin | 54.81% | 53.66% | 53.17% | 55.16% | 59.60% | 62.48% |
Operating Margin | 37.79% | 39.06% | 39.88% | 43.65% | 49.03% | 51.39% |
Profit Margin | 30.70% | 32.94% | -4.86% | 36.68% | 37.20% | 30.92% |
Free Cash Flow Margin | 24.73% | 26.61% | -7.17% | 33.81% | 43.95% | 31.80% |
EBITDA | 5,101 | 4,866 | 4,577 | 4,477 | 4,527 | 4,018 |
EBITDA Margin | 39.38% | 40.55% | 41.53% | 45.36% | 50.69% | 53.05% |
D&A For EBITDA | 206.1 | 178.6 | 182 | 169.5 | 148.3 | 125.6 |
EBIT | 4,895 | 4,687 | 4,395 | 4,308 | 4,378 | 3,892 |
EBIT Margin | 37.79% | 39.06% | 39.88% | 43.65% | 49.03% | 51.39% |
Effective Tax Rate | 16.46% | 14.86% | 315.53% | 17.36% | 21.51% | 14.22% |
Revenue as Reported | 12,952 | 12,001 | 11,020 | 9,869 | - | 7,574 |